Public Employees Retirement Association of Colorado Has $289,000 Position in Intrexon Corp (XON)
Public Employees Retirement Association of Colorado reduced its position in shares of Intrexon Corp (NYSE:XON) by 0.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,994 shares of the biotechnology company’s stock after selling 69 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Intrexon Corp were worth $289,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently made changes to their positions in XON. State Street Corp increased its stake in shares of Intrexon Corp by 34.0% in the first quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock worth $53,664,000 after buying an additional 687,406 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Intrexon Corp by 5.6% in the first quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock worth $84,954,000 after buying an additional 226,090 shares in the last quarter. First Trust Advisors LP increased its stake in shares of Intrexon Corp by 15.9% in the first quarter. First Trust Advisors LP now owns 1,160,308 shares of the biotechnology company’s stock worth $22,997,000 after buying an additional 158,964 shares in the last quarter. Credit Suisse AG increased its stake in shares of Intrexon Corp by 273.7% in the first quarter. Credit Suisse AG now owns 183,555 shares of the biotechnology company’s stock worth $3,638,000 after buying an additional 134,434 shares in the last quarter. Finally, Iridian Asset Management LLC CT increased its stake in shares of Intrexon Corp by 2.4% in the first quarter. Iridian Asset Management LLC CT now owns 3,853,274 shares of the biotechnology company’s stock worth $76,372,000 after buying an additional 91,565 shares in the last quarter. Institutional investors and hedge funds own 82.27% of the company’s stock.
Intrexon Corp (NYSE XON) opened at 19.17 on Thursday. The company’s market capitalization is $2.31 billion. Intrexon Corp has a 52 week low of $17.03 and a 52 week high of $32.90. The stock’s 50 day moving average is $21.13 and its 200 day moving average is $21.71.
Intrexon Corp (NYSE:XON) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Intrexon Corp had a negative return on equity of 13.87% and a negative net margin of 30.00%. The firm had revenue of $54.40 million during the quarter, compared to analysts’ expectations of $57.17 million. During the same quarter in the previous year, the business earned ($0.42) earnings per share. The company’s revenue was up 3.6% on a year-over-year basis. Analysts predict that Intrexon Corp will post ($0.87) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/public-employees-retirement-association-of-colorado-has-289000-position-in-intrexon-corp-xon/1532925.html.
A number of analysts recently weighed in on XON shares. BidaskClub upgraded shares of Intrexon Corp from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 15th. Zacks Investment Research downgraded shares of Intrexon Corp from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Northland Securities set a $30.00 price target on shares of Intrexon Corp and gave the company a “buy” rating in a research report on Monday, August 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Intrexon Corp presently has a consensus rating of “Hold” and a consensus price target of $37.60.
In other Intrexon Corp news, Director Robert B. Shapiro purchased 2,850 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was purchased at an average price of $17.50 per share, for a total transaction of $49,875.00. Following the completion of the purchase, the director now directly owns 43,157 shares of the company’s stock, valued at $755,247.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Andrew J. Last purchased 2,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was acquired at an average price of $19.99 per share, with a total value of $39,980.00. Following the purchase, the chief operating officer now directly owns 2,000 shares of the company’s stock, valued at $39,980. The disclosure for this purchase can be found here. Insiders bought 144,569 shares of company stock valued at $2,719,429 in the last 90 days. Company insiders own 56.30% of the company’s stock.
About Intrexon Corp
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.